CanSino Biologics Inc. (“CanSinoBIO”) announced that its subsidiary, CanSino (Shanghai) Biological Research Co., Ltd., has officially signed a licensing agreement with PanRu Biotechnology (Tianjin) Co., Ltd. (PanRu Biotech). Under the agreement, CanSinoBIO grants Panru Biotech the license to use its independently developed innovative three-component lipid nanoparticle delivery system (ISL-3C-LNP), aiming to expand the broader application prospects of this novel delivery platform. This collaboration is expected to bring CanSinoBIO proceeds exceeding RMB 100 million over the coming years, including upfront and milestone payments.

This licensing agreement marks another important milestone for CanSinoBIO in the field of mRNA delivery technology. Under the agreement, PanRu Biotech is authorized to use the ISL-3C-LNP as the core lipid formulation for its therapeutic mRNA vaccine program (PRBT001 injection) targeting prostate cancer, covering global research and development, manufacturing, and commercialization. In parallel, CanSinoBIO will leverage its mRNA technology platform to provide customized development and production support for the project.

Based on ionizable sterol lipid (ISL) compounds, CanSinoBIO has constructed a three-component system that overcomes the patent barrier of conventional four-component LNPs (4C-LNPs). This innovative delivery system not only addresses the patent constraints of traditional LNPs but also offers enhanced immunogenicity and improved safety profiles, providing new insights for the design and development of next-generation mRNA vaccines. It shows particular promise in therapeutic areas requiring strong cellular immune responses, such as tumor immunotherapy.

The two companies previously collaborated during the early clinical stage of the project. This licensing partnership will further support the accumulation of clinical data, expand potential collaborations, and facilitate continued optimization and iteration of the platform.

CanSinoBIO stated that it will continue to advance research on the mechanisms of ISL-3C-LNP and leverage its proprietary mRNA technology platform to drive ongoing innovation and broader applications of delivery systems. By strengthening its external collaboration networks, CanSinoBIO aims to facilitate the development and industrialization of solutions for infectious disease prevention, tumor immunotherapy, and other therapeutic areas, thereby contributing to sustainable biopharmaceutical innovation and global public health.